- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05055219
Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance
14. september 2021 opdateret af: Joyce Lee, University of Michigan
The purpose of this study is to evaluate the longitudinal test performance of an array of conventional biomarkers of glycemia, including Hemoglobin A1c (HbA1c), and novel metabolomic biomarkers for identifying progression of glucose tolerance (normal to prediabetes or prediabetes to diabetes) in an overweight and obese pediatric cohort.
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
772
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- University of Michigan
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
8 år til 22 år (Barn, Voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
The study population will consist of normal weight, overweight or obese individuals aged 8 to 17 years at visits #1 and #2, and can be as old as 22 years for follow-up visits #3 and #4.
Participants will be recruited from a variety of sites including University Michigan clinical sites, non-University of Michigan clinical sites, schools in the local area, and the University Michigan medical school campus.
Participants from Group 2 (visits #3-4) completed visits #1-2 in 2007-2013 and formally agreed to be re-contacted for study purposes.
Beskrivelse
Inclusion Criteria:
- Groups 1 and 2 (overweight and obese groups):
- Age 8-17 years for the visits #1 and #2, individuals can be as old as 22 years for follow-up visits #3 and 4
- Overweight or obese, as defined by a BMI ≥ 85th% & <95th% or BMI ≥ 95th%, respectively by age and sex, and for those 16 years and older, BMI ≥25 and <30 and BMI ≥30
- For Group 2 only: previously completed visits 1-2 in 2007-2013 and formally agreed to be re-contacted for study purposes
- Group 3 (Normal weight controls):
- Age 8-17 years
- Healthy weight, as defined by a BMI ≥ 5th percentile & < 85th percentile, respectively by age and sex
Exclusion Criteria:
- Previous diagnosis of type 1 diabetes
- Use of concurrent medications known to affect glucose metabolism (metformin, oral steroids, sulfonylureas, insulin)
- Verbal report of Pregnancy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Group 1: Overweight or Obese Group (visits #1-4)
Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight.
Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively.
Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
|
Group 2: Overweight or Obese Group (visits #3-4)
Children and young adults who are 8 to 22 years of age, who have risk factors for diabetes such as being overweight, or children and young adults who previously participated in the study (completed visits #1-2 in previous study phase).
Overweight or obese, as defined by a BMI ≥ 85th percentile & <95th percentile or BMI ≥ 95th percentile, respectively.
Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
|
Group 3: Normal Weight Control Group
Children and adolescents who are 8 to 17 years of age, who have do not have risk factors for diabetes such as being overweight or a history of type 2 diabetes in the family.
Healthy weight, as defined by a BMI ≥ 5th percentile & < 85th percentile.
Study participants cannot be pregnant or currently take medications known to affect glucose metabolism including, metformin, oral steroids, sulfonylureas, and insulin.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression of glucose tolerance
Tidsramme: Up to 5 years
|
Normal glucose tolerance, prediabetes, or diabetes
|
Up to 5 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Joyce Lee, MD, MPH, University of Michigan
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. juni 2015
Primær færdiggørelse (Faktiske)
19. februar 2020
Studieafslutning (Faktiske)
19. februar 2020
Datoer for studieregistrering
Først indsendt
14. september 2021
Først indsendt, der opfyldte QC-kriterier
14. september 2021
Først opslået (Faktiske)
24. september 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
24. september 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. september 2021
Sidst verificeret
1. september 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HUM00006955
- 5R01HD074559-05 (U.S. NIH-bevilling/kontrakt)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .